Navigation Links
ChanTest Initiates Project for the US FDA to Improve Understanding of the Interaction of Tobacco Products with Human Nicotinic Receptors
Date:8/20/2013

Cleveland (PRWEB) August 20, 2013

ChanTest, a Contract Research Organization and world leader in ion channel drug safety and discovery, announces initiation of a project funded by the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP). CTP’s mission is to improve our understanding of the pharmacology of tobacco product substituent compounds and to enhance the regulation of tobacco products.

The FDA’s authority to regulate the manufacture, distribution, and marketing of tobacco products to protect public health stems from The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), which became law on June 22, 2009. The FDA's funding of this ChanTest project falls under a regulatory science initiative calling for innovation in technology to convert basic science to real-world applications.

The goals of the one-year study are to develop cell lines that express human nicotinic receptor subtypes, and to optimize high-throughput testing of exploratory compounds against nicotinic receptors in automated patch clamp and fluorometric plate-based assays. The results of the study will help the FDA gain a better understanding of the pharmacology of human nicotinic receptor subtypes and provide screening platforms for efficient characterization of tobacco-related substances.

“This project will expand our repertoire of ligand-gated ion channel test systems in the therapeutically important neuronal nicotinic receptor family. We look forward to benefiting from FDA’s extensive background in this class of targets” said ChanTest Director of Pharmacology, Glenn Kirsch, Ph.D.

Dr. Arthur “Buzz” Brown, M.D., Ph.D., ChanTest Founder and CEO, added “ChanTest has unique expertise in ion channel cell line development and cell-based functional assays, as demonstrated by our track record in ion channel safety and discovery services serving the pharmaceutical industry. We view th
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
2. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. ChanTest Develops New Cardiotoxicity and Contractility Assay with Human Stem Cell Cardiomyocytes
5. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
7. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
8. Applied Genetics Initiates Commercial Operation
9. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
10. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
11. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... 2014 Gain recognition for leadership ... of the biotech industry. Nominations are now being ... to you by the Bio Supply Management ... chain management professionals for the past 7 years. ... the Biotech industry – Manufacturers, Service Providers, Material ...
(Date:7/24/2014)... 24, 2014  ECC West Africa, LLC (ECC) signed ... with University College Hospital (UCH) Ibadan Board of Management ... finance, design, construct, and operate and maintain a new, ... . Under the first of the 4-phase project, ECC ... funding applications. UCH Ibadan intends to finance and develop ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... caused by mutations in the gene responsible for making ... and developing new therapies has been hampered by the ... fail to develop many of the symptoms seen in ... April issue of the Journal of Clinical Investigation have ...
... 6 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) today ... treat bronchiectasis has been accepted for evaluation by,China,s ... pharmaceutical companies are required to undertake a study ... application.,Approval of the clinical trial application is expected ...
... PALO ALTO, Calif., March 6 Jazz,Pharmaceuticals, Inc. ... the,public to a live webcast of the company,s ... 10:00 a.m. Eastern Time/7:00 a.m.,Pacific Time on Thursday, ... last,approximately two hours., Members of Jazz Pharmaceuticals, ...
Cached Biology Technology:Pharmaxis' First Steps into China 2
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
(Date:7/24/2014)... 3.5 billion years of evolutionary trial and error, is ... may be reaching a tipping point. , In a ... published in Science , an international team of ... is contributing to what appears to be the early ... , Since 1500, more than 320 terrestrial vertebrates have ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... of the body, the great majority of genes are silenced, ... up chromosomes. Estimates are that only about 10 percent of ... or "on," at any given time in a particular cell ... , Reliable gene silencing is vital to the health of ...
... have discovered a gene in fruit flies that helps ... The study, published in the April 4 issue of ... in mammals. , In teasing apart the molecular interactions ... gene they dubbed "Lazaro" that is expressed 15 times ...
... industry, including cruise lines, local governments and shore ... are taking proactive measures to ensure a sustainable ... according to a new report titled From Ship ... by Conservation International's (CI) Center for Environmental Leadership ...
Cached Biology News:New mechanism for essential genome-wide gene silencing identified 2New gene reduces retinal degeneration in fruit flies 2Report finds cruise industry is protecting the precious places it visits 2Report finds cruise industry is protecting the precious places it visits 3Report finds cruise industry is protecting the precious places it visits 4
...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Biology Products: